| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| b' Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sab\\xc3\\xa. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 76. 2023-08-09. PMID:37557019.' |
psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. |
2023-08-09 |
2023-08-16 |
human |
| b' Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sab\\xc3\\xa. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 76. 2023-08-09. PMID:37557019.' |
we conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. |
2023-08-09 |
2023-08-16 |
human |
| b' Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sab\\xc3\\xa. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 76. 2023-08-09. PMID:37557019.' |
following our protocol (crd 42022220190) multiple electronic databases were searched from their inception until february 2023, to identify double-blind randomized placebo-controlled (rcts) fixed-dose trials evaluating the use of psilocybin for adult patients with primary or secondary depression. |
2023-08-09 |
2023-08-16 |
human |
| Otto Simonsson, Per Carlbring, Robin Carhart-Harris, Alan K Davis, David J Nutt, Roland R Griffiths, David Erritzoe, Simon B Goldber. Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. Psychiatry research. vol 327. 2023-07-31. PMID:37523886. |
we conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (n = 102) with the aim of assessing the risk of symptom worsening. |
2023-07-31 |
2023-08-14 |
human |
| Muhammad Ishrat Husain, Daniel M Blumberger, David J Castle, Nicole Ledwos, Elise Fellows, Brett D M Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D Rosenblat, Benoit H Mulsan. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych open. vol 9. issue 4. 2023-07-25. PMID:37489299. |
psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. |
2023-07-25 |
2023-08-14 |
Not clear |
| Muhammad Ishrat Husain, Daniel M Blumberger, David J Castle, Nicole Ledwos, Elise Fellows, Brett D M Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D Rosenblat, Benoit H Mulsan. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych open. vol 9. issue 4. 2023-07-25. PMID:37489299. |
randomised controlled trials (rcts) of psilocybin have reported large antidepressant effects in adults with major depressive disorder and treatment-resistant depression (trd). |
2023-07-25 |
2023-08-14 |
Not clear |
| Brandon Weiss, Induni Ginige, Lu Shannon, Bruna Giribaldi, Ashleigh Murphy-Beiner, Roberta Murphy, Michelle Baker-Jones, Jonny Martell, David J Nutt, Robin L Carhart-Harris, David Erritzo. Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM. Psychological medicine. 2023-07-19. PMID:37466289. |
personality change in a trial of psilocybin therapy vs escitalopram treatment for depression - corrigendum. |
2023-07-19 |
2023-08-14 |
Not clear |
| Guy M Goodwin, Megan Croal, David Feifel, John R Kelly, Lindsey Marwood, Sunil Mistry, Veronica O'Keane, Stephanie Knatz Peck, Hollie Simmons, Claudia Sisa, Susan C Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskai. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-07-14. PMID:37443386. |
psilocybin for treatment resistant depression in patients taking a concomitant ssri medication. |
2023-07-14 |
2023-08-14 |
human |
| Guy M Goodwin, Megan Croal, David Feifel, John R Kelly, Lindsey Marwood, Sunil Mistry, Veronica O'Keane, Stephanie Knatz Peck, Hollie Simmons, Claudia Sisa, Susan C Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskai. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-07-14. PMID:37443386. |
psilocybin is being investigated as a treatment in adults with treatment-resistant depression (trd). |
2023-07-14 |
2023-08-14 |
human |
| Bianca Nograd. Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics. BMJ (Clinical research ed.). vol 382. 2023-07-11. PMID:37433614. |
australia's approval of mdma and psilocybin for ptsd and depression is premature, say critics. |
2023-07-11 |
2023-08-14 |
Not clear |
| Patrick D Skosnik, Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania, Shariful Syed, Brian Pittman, Deepak C D'Souz. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal of psychopharmacology (Oxford, England). 2023-07-01. PMID:37392016. |
sub-acute effects of psilocybin on eeg correlates of neural plasticity in major depression: relationship to symptoms. |
2023-07-01 |
2023-08-14 |
Not clear |
| Harrison J Lee, Vivian Wl Tsang, Brandon S Chai, Michelle Cq Lin, Andrew Howard, Christopher Uy, Julius O Elefant. Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review. Journal of psychoactive drugs. 2023-06-29. PMID:37385217. |
psilocybin's potential mechanisms in the treatment of depression: a systematic review. |
2023-06-29 |
2023-08-14 |
human |
| Harrison J Lee, Vivian Wl Tsang, Brandon S Chai, Michelle Cq Lin, Andrew Howard, Christopher Uy, Julius O Elefant. Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review. Journal of psychoactive drugs. 2023-06-29. PMID:37385217. |
evidence suggests that psilocybin has therapeutic benefit for treating depression. |
2023-06-29 |
2023-08-14 |
human |
| Rich Harid. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 2023-06-29. PMID:37386185. |
australia to prescribe mdma and psilocybin for ptsd and depression in world first. |
2023-06-29 |
2023-08-14 |
Not clear |
| Anya Borissova, James J Rucke. The development of psilocybin therapy for treatment-resistant depression: an update. BJPsych bulletin. 2023-06-26. PMID:37357767. |
the development of psilocybin therapy for treatment-resistant depression: an update. |
2023-06-26 |
2023-08-14 |
human |
| Anya Borissova, James J Rucke. The development of psilocybin therapy for treatment-resistant depression: an update. BJPsych bulletin. 2023-06-26. PMID:37357767. |
initial phase 2 clinical trials of psilocybin given alongside psychological support for major depression and treatment-resistant depression (trd) demonstrated encouraging signs of basic safety, further confirmed by a large study in groups of healthy volunteers. |
2023-06-26 |
2023-08-14 |
human |
| Sandeep M Nayak, Bilal A Bari, David B Yaden, Meg J Spriggs, Fernando E Rosas, Joseph M Peill, Bruna Giribaldi, David Erritzoe, David J Nutt, Robin Carhart-Harri. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression. Psychedelic medicine (New Rochelle, N.Y.). vol 1. issue 1. 2023-06-20. PMID:37337526. |
a bayesian reanalysis of a trial of psilocybin versus escitalopram for depression. |
2023-06-20 |
2023-08-14 |
Not clear |
| Brandon Weiss, Induni Ginige, Lu Shannon, Bruna Giribaldi, Ashleigh Murphy-Beiner, Roberta Murphy, Michelle Baker-Jones, Jonny Martell, David J Nutt, Robin L Carhart-Harris, David Erritzo. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological medicine. 2023-06-02. PMID:37264814. |
personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. |
2023-06-02 |
2023-08-14 |
Not clear |
| Paul McCrone, Henry Fisher, Clare Knight, Rebecca Harding, Anne K Schlag, David J Nutt, Joanna C Neil. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychological medicine. 2023-06-02. PMID:37264950. |
there is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. |
2023-06-02 |
2023-08-14 |
Not clear |
| Olivier Brow. Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression". Journal of affective disorders. 2023-05-31. PMID:37257781. |
letter to the editor on "increased low-frequency brain responses to music after psilocybin therapy for depression". |
2023-05-31 |
2023-08-14 |
Not clear |